Literature DB >> 3971296

Experience with continuous regional chemotherapy and hepatic resection as treatment of hepatic metastases from colorectal primaries. A prospective randomized study.

M M Kemeny, D A Goldberg, S Browning, G E Metter, P J Miner, J J Terz.   

Abstract

Sixty-five patients with hepatic metastases from colorectal primaries were studied in a prospective randomized fashion. The five patients with solitary metastases all had resection of metastases and 50% were randomized to pump therapy. Of the 16 patients with multiple resectable metastases, 7 had pump only and 9 had resection plus pump. Although the difference was not significant, there was a trend of improved survival for the patients with resection plus pump. For the patients with unresectable disease, those patients with positive portal nodes had poor survival matching those patients with extra hepatic metastases. Patients with unresectable disease treated with pump had a 73% therapeutic response rate and a median survival of 22 months. Significant complications included chemical hepatitis and biliary stenosis. The long-term efficacy of continuous hepatic artery infusion versus the hazards of treatment and the financial cost will need further investigation.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3971296     DOI: 10.1002/1097-0142(19850315)55:6<1265::aid-cncr2820550619>3.0.co;2-r

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  10 in total

1.  [Regional chemotherapy of liver metastases].

Authors:  A Encke; C Hottenrott; M Lorenz
Journal:  Langenbecks Arch Chir       Date:  1987

Review 2.  Colorectal cancer with liver metastases: neoadjuvant chemotherapy, surgical resection first or palliation alone?

Authors:  Khurum Khan; Anita Wale; Gina Brown; Ian Chau
Journal:  World J Gastroenterol       Date:  2014-09-21       Impact factor: 5.742

Review 3.  Hepatic arterial infusional chemotherapy in the management of colorectal cancer liver metastases.

Authors:  Alexandre Doussot; Nancy E Kemeny; Michael I D'Angelica
Journal:  Hepat Oncol       Date:  2015-07-27

4.  Metabolism of 5-fluorouracil to an N-cholyl-2-fluoro-beta-alanine conjugate: previously unrecognized role for bile acids in drug conjugation.

Authors:  D J Sweeny; S Barnes; G D Heggie; R B Diasio
Journal:  Proc Natl Acad Sci U S A       Date:  1987-08       Impact factor: 11.205

5.  Arterial, portal or combined arterio-portal regional chemotherapy in experimental liver tumours?

Authors:  T Riemenschneider; C Ruf; H C Kratzsch; M Ziegler; G Späth
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

6.  Preoperative staging with computerized axial tomography and biochemical laboratory tests in patients with hepatic metastases.

Authors:  M M Kemeny; J M Hogan; L Ganteaume; D A Goldberg; J J Terz
Journal:  Ann Surg       Date:  1986-02       Impact factor: 12.969

7.  Sclerosing cholangitis after continuous hepatic artery infusion of FUDR.

Authors:  M M Kemeny; H Battifora; D W Blayney; G Cecchi; D A Goldberg; L A Leong; K A Margolin; J J Terz
Journal:  Ann Surg       Date:  1985-08       Impact factor: 12.969

8.  Continuous or bolus chemotherapy with 5-fluoro-2'-deoxyuridine in transplanted experimental liver tumors?

Authors:  T Riemenschneider; C Ruf; G Späth; G Stuhldreier; A Elmouaouy
Journal:  J Cancer Res Clin Oncol       Date:  1988       Impact factor: 4.553

Review 9.  Clinical pharmacology of 5-fluorouracil.

Authors:  R B Diasio; B E Harris
Journal:  Clin Pharmacokinet       Date:  1989-04       Impact factor: 6.447

10.  Cryotherapy for liver metastases.

Authors:  Malgorzata M Bala; Robert P Riemsma; Robert Wolff; Michal Pedziwiatr; Jerzy W Mitus; Dawid Storman; Mateusz J Swierz; Jos Kleijnen
Journal:  Cochrane Database Syst Rev       Date:  2019-07-10
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.